Search

Your search keyword '"Moris, Maria"' showing total 3 results
Start Over Author "Moris, Maria" Topic adenocarcinoma
3 results on '"Moris, Maria"'

1. Plectin-1 as a Biomarker of Malignant Progression in Intraductal Papillary Mucinous Neoplasms

Author

Moris, Maria, Dawson, David W, Jiang, Jennifer, Lewis, Jason, Nassar, Aziza, Takeuchi, Kenneth K, Lay, Anna R, Zhai, Qihui, Donahue, Timothy R, Kelly, Kimberly A, Crawford, Howard C, and Wallace, Michael

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Patient Safety, Digestive Diseases, Rare Diseases, Adenocarcinoma, Mucinous, Biomarkers, Tumor, Carcinoma, Pancreatic Ductal, Humans, Pancreatic Neoplasms, Plectin, Plectin-1, intraductal papillary mucinous neoplasm, biomarker, immunohistochemistry, branch duct IPMN, malignant progression, pancreatic adenocarcinoma, Gastroenterology & Hepatology, Clinical sciences
Abstract

ObjectiveThis study aimed to evaluate Plectin-1 expression as a biomarker of malignant risk for intraductal papillary mucinous neoplasms (IPMNs).MethodsPlectin-1 immunohistochemistry (IHC) was performed retrospectively on surgical (n = 71) and cytological (n = 33) specimens from Mayo Clinic Jacksonville and UCLA Medical Center, including IPMNs with low-grade dysplasia, high-grade dysplasia (HGD), or an associated invasive adenocarcinoma.ResultsPlectin-1 expression was increased in invasive adenocarcinoma compared with adjacent in situ IPMN (P = 0.005), as well as the in situ HGD component of IPMNs with invasive cancer compared with HGD of IPMNs without invasive cancer (P = 0.02). Plectin IHC discriminated IPMNs with invasive adenocarcinoma from noninvasive IPMN (area under the curve [AUC] of 0.79, 75% sensitivity, and 85% specificity) but was insufficient for discriminating HGD IPMN from low-grade dysplasia IPMNs in surgical resections (AUC of 0.67, 56% sensitivity, and 64% specificity) or fine-needle aspiration specimens (AUC of 0.45).ConclusionsAlthough Plectin-1 IHC has insufficient accuracy to be used as a definitive biomarker for malignant risk in the evaluation of IPMN biopsy or cytological specimens, increased Plectin-1 expression observed in both invasive cancer and in situ HGD of malignant IPMNs suggests that it might be successfully leveraged as a cyst fluid biomarker or molecular imaging target.

Published
2016

2. International Intraductal Papillary Mucinous Neoplasms Registry

Author

Selene Manfrè, Claudio De Angelis, Pietro Fusaroli, Maria Chiara Petrone, Massimo Raimondo, Silvia Carrara, Paolo Giorgio Arcidiacono, Maria Moris, Manol Jovani, Verna Skinner, Timothy A. Woodward, Michael B. Wallace, Moris, Maria, Raimondo, Massimo, Woodward, Timothy A., Skinner, Verna J., Arcidiacono, Paolo G., Petrone, Maria C., de Angelis, Claudio, Manfrè, Selene, Carrara, Silvia, Jovani, Manol, Fusaroli, Pietro, and Wallace, Michael B.

Subjects
Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Malignancy, Main duct, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal Medicine, Carcinoma, medicine, Humans, Cyst, Longitudinal Studies, Registries, Aged, Gastrointestinal Neoplasms, Retrospective Studies, Hepatology, Intraductal papillary mucinous neoplasm, business.industry, Retrospective cohort study, Long term results, medicine.disease, Adenocarcinoma, Mucinous, Surgery, Pancreatic Neoplasms, Adenocarcinoma, Papillary, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, Disease Progression, Adenocarcinoma, Female, 030211 gastroenterology & hepatology, Radiology, Pancreatic Cyst, business, Carcinoma, Pancreatic Ductal, Follow-Up Studies
Abstract

OBJECTIVE: The aim of this study was to analyze the outcomes of a long-term intraductal papillary mucinous neoplasm (IPMN) registry and evaluate new guidelines. METHODS: A prospectively maintained IPMN registry involving 6 centers in Europe and the United States was used to collect the data. Patients with more than 1-year follow-up and no malignancy diagnosed within the first 3 months of surveillance were included. RESULTS: From 1999 to 2014, 620 patients were included. The median follow-up time was 3 years. Thirty-seven (6%) patients developed malignancy with a median time from IPMN diagnosis to malignancy of 10.3 months. The 1-, 5-, and 10-year actuarial rates of disease-free survival were 97%, 93%, and 92% respectively. Four hundred thirty-one patients met criteria for low-risk branch duct IPMN consisting of cyst size less than 3 cm, with no solid component or main duct dilation. Eight malignancies were diagnosed in this subgroup, all of them within the first 5 years. From this subcohort, 112 patients had a follow-up time of more than 5 years, and no malignancy was diagnosed. CONCLUSIONS: In IPMN lesions with low-risk features at baseline, the risk of progression to malignancy after the first 5 years of follow-up was minimal. Furthermore, the main cyst characteristics remained unchanged during their surveillance.

Published
2017

3. Diagnostic Accuracy of Endoscopic Ultrasound-Guided Fine-Needle Aspiration Cytology, Carcinoembryonic Antigen, and Amylase in Intraductal Papillary Mucinous Neoplasm

Author

Michael B. Wallace, Verna Skinner, Massimo Raimondo, Horacio J. Asbun, Selene Manfrè, Paolo Giorgio Arcidiacono, Maria Chiara Petrone, Maria Moris, Timothy A. Woodward, Pietro Fusaroli, John A. Stauffer, Claudio De Angelis, Moris, Maria, Raimondo, Massimo, Woodward, Timothy A., Skinner, Verna, Arcidiacono, Paolo G., Petrone, Maria C., De Angelis, Claudio, Manfrè, Selene, Fusaroli, Pietro, Asbun, Horacio, Stauffer, John, Wallace, Michael B, Moris, M, Raimondo, M, Woodward, Ta, Skinner, V, Arcidiacono, P. G., Petrone, Mc, De Angelis, C, Manfrè, S, Fusaroli, P, Asbun, H, Stauffer, J, and Wallace, Mb.

Subjects
Male, Endoscopic ultrasound, medicine.medical_specialty, Pathology, endocrine system diseases, Endocrinology, Diabetes and Metabolism, specificity, Sensitivity and Specificity, 03 medical and health sciences, 0302 clinical medicine, Carcinoembryonic antigen, Endocrinology, Cytology, medicine, Carcinoma, Internal Medicine, Humans, Cyst, Endoscopic Ultrasound-Guided Fine Needle Aspiration, Pancreas, EUS, Aged, cyst, Intraductal papillary mucinous neoplasm, biology, medicine.diagnostic_test, Hepatology, business.industry, IPMN, Reproducibility of Results, Middle Aged, medicine.disease, sensitivity, Adenocarcinoma, Mucinous, Carcinoma, Papillary, Carcinoembryonic Antigen, Pancreatic Neoplasms, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Amylases, biology.protein, Adenocarcinoma, Female, 030211 gastroenterology & hepatology, Radiology, business, Carcinoma, Pancreatic Ductal
Abstract

Objectives The aim of this study was to determine the accuracy of cytology, carcinoembryonic antigen (CEA), and amylase levels in the preoperative diagnosis of intraductal papillary mucinous neoplasms (IPMNs). Methods An international registry was started in 2005 and included patients with clinically suspected IPMNs. Those who underwent surgery and had preoperative endoscopic ultrasonography fine-needle aspiration were selected for the study. Results One hundred eighty patients were included. Cytological analysis for neoplastic cells in IPMNs showed high specificity (87.8%) but low sensitivity (39.4%). The median CEA level was 525.5 ng/mL (n = 78) in IPMNs versus 9.7 ng/mL in nonmucinous cysts (n = 6), showing an area under the receiver operating characteristic curve (AUC) of 0.87. The optimal cutoff CEA value for distinguishing IPMN from nonmucinous cysts was 129 ng/mL. At this level, the sensitivity was 76.9%, and specificity was 83.3%, yielding a positive predictive value of 95.9% and a negative predictive value of 41.9%. Carcinoembryonic antigen was a poor predictor of neoplasia in IPMNs (AUC = 0.55). Amylase did not distinguish IPMNs from mucinous cystadenomas (MCAs) (median, 3759 U/L [n = 28 IPMNs] and 497 U/L [n = 3 MCAs], AUC = 0.65). Conclusions Cytology has a limited role because of its lack of sensitivity. Carcinoembryonic antigen modestly differentiated between mucinous and nonmucinous lesions. Amylase did not distinguish IPMNs versus MCAs.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results